Clinical Trial

Shatavari Root Extract for Perimenopausal Symptoms

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 3, 2026 (before its estimated June 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This randomized, double-blind, placebo-controlled clinical study evaluates the efficacy and safety of a standardized Shatavari (Asparagus racemosus) root extract in women experiencing perimenopausal symptoms. Participants will receive either Shatavari root extract or a matched placebo for 12 weeks. Efficacy will be assessed using validated menopause-specific symptom, quality-of-life, stress, mood, and sleep questionnaires, along with physiological stress markers. Safety will be evaluated through laboratory assessments and adverse event monitoring.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-23.
Trial Details
NCT Number NCT07441109
Lead Sponsor SF Research Institute, Inc.
Collaborators: Ixoreal Biomed Private Limited
Conditions Perimenopause, Women Health
Enrollment 60 participants
Start Date 2026-03-11
Primary Completion 2026-06-15 (estimated)
Study Completion 2026-06-29 (estimated)
Updated on ClinicalTrials.gov 2026-03-03